Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Respiratory Assessment: Purpose and Indications01:19

Respiratory Assessment: Purpose and Indications

Respiratory assessment is a cornerstone of nursing assessments, crucial for the early detection of patient deterioration. This evaluation transcends routine procedures, representing a critical skill nurses must master to ensure optimal patient care.
Objectives and Importance:
The primary goal of respiratory assessment is to evaluate patients at early risk of clinical deterioration. Since respiratory distress often precedes other signs of declining health, breathing patterns and sounds become a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Closing the loop: Understanding ostomy reversal rates and risks in trauma patients.

The journal of trauma and acute care surgery·2026
Same author

Diaphragm stimulation after human spinal cord injury: Effects on respiratory function and diaphragm muscle activation.

The journal of trauma and acute care surgery·2026
Same author

Adherence of Impulse Control in Primary Management of Grade I and II Blunt Thoracic Aortic Injury.

The Journal of surgical research·2026
Same author

Off-Road Vehicle Trauma in Southern California: Association With the Social Vulnerability Index.

The American surgeon·2026
Same author

PEX11 mediates intralumenal vesicle formation in peroxisomes.

Nature communications·2026
Same author

Disparities in Revision Arthroplasty: A Scoping Review of Racial, Sex-Based, and Geographic Domains.

Current reviews in musculoskeletal medicine·2026

Related Experiment Video

Updated: May 18, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

Inhaled epoprostenol improves oxygenation in severe hypoxemia.

Maryam Bita Tabrizi1, Miren A Schinco, Joseph J Tepas

  • 1Department of Surgery, University of Florida Health Sciences Center, Jacksonville, Florida, USA.

The Journal of Trauma and Acute Care Surgery
|September 29, 2012
PubMed
Summary
This summary is machine-generated.

Inhaled epoprostenol effectively improved oxygenation in severely hypoxemic surgical patients. Early treatment within 7 days of intubation yielded the best results for improving gas exchange.

Related Experiment Videos

Last Updated: May 18, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

Area of Science:

  • Critical Care Medicine
  • Pulmonary Medicine
  • Pharmacology

Background:

  • Severe hypoxemia in ventilated surgical patients necessitates effective oxygenation strategies.
  • Inhaled epoprostenol offers a potential alternative to nitric oxide for improving pulmonary hemodynamics and gas exchange.
  • Evaluating inhaled epoprostenol's efficacy and cost-effectiveness in surgical intensive care units is crucial.

Purpose of the Study:

  • To assess the benefits of inhaled epoprostenol in mechanically ventilated surgical patients with severe hypoxemia.
  • To compare inhaled epoprostenol with nitric oxide as a less expensive therapeutic option.
  • To determine the impact of inhaled epoprostenol on oxygenation and pulmonary pressures.

Main Methods:

  • Retrospective review of 36 mechanically ventilated surgical intensive care unit patients treated with inhaled epoprostenol for severe hypoxemia (SaO₂ < 90%).
  • Comparison of initial PaO₂/FIO₂ (P/F) ratio and oxygen saturation with values at 12 and 48 hours post-administration.
  • Subgroup analyses included trauma vs. nontrauma patients, time to initiation, and age groups.

Main Results:

  • Inhaled epoprostenol significantly improved P/F ratio and oxygen saturation in both trauma and nontrauma patients.
  • Earlier initiation of epoprostenol (within 7 days) correlated with greater improvements in P/F ratio.
  • No significant differences in mortality or response were observed between trauma and nontrauma subgroups or across age groups.

Conclusions:

  • Inhaled epoprostenol is an effective treatment for improving gas exchange in severely hypoxemic surgical patients.
  • Timely intervention with inhaled epoprostenol, ideally within 7 days of intubation, enhances its efficacy.
  • Further research may explore inhaled epoprostenol's role in optimizing outcomes for specific patient populations.